Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TESTOSTERONE CYPIONATE vs DOXAZOSIN MESYLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.
Male hypogonadism (primary or hypogonadotropic),Delayed puberty in males,Off-label: Female-to-male gender affirmation therapy, anemia of renal failure (historically)
Hypertension,Benign prostatic hyperplasia (BPH),Off-label: Pheochromocytoma (preoperative management), Raynaud's phenomenon, ureteral stones
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Terminal elimination half-life is approximately 22 hours. This long half-life supports once-daily dosing for hypertension and benign prostatic hyperplasia.
Primarily hepatic via CYP3A4 and CYP2B6; metabolites include androsterone and etiocholanolone; excreted in urine.
Extensively metabolized in the liver via O-demethylation and hydroxylation, primarily by CYP3A4.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Approximately 63% of the dose is excreted in feces via biliary elimination, and about 9% is excreted unchanged in urine. The remainder is metabolized, with metabolites excreted in urine and feces.
97-99% bound to sex hormone-binding globulin (SHBG) and albumin
Approximately 98-99% bound to plasma proteins, primarily albumin.
Approximately 0.6-1.0 L/kg (reflects extensive distribution into tissues, including muscle and fat; total Vd ~4-9 L in adults)
0.5-1.5 L/kg, indicating extensive distribution into tissues and extravascular spaces.
Intramuscular: 100% (administered as a depot injection in oil; undergoes first-pass metabolism if oral, but not relevant for IM route)
Oral bioavailability is approximately 65% due to first-pass metabolism. Food does not significantly affect absorption.
No specific dose adjustment recommended; however, monitor fluid retention and hypertension in patients with severe renal impairment (GFR <30 m L/min).
No dose adjustment needed for renal impairment. Doxazosin is minimally renally excreted.
Child-Pugh A/B: No adjustment; Child-Pugh C: Contraindicated due to risk of hepatotoxicity.
Contraindicated in severe hepatic impairment (Child-Pugh C). In mild-moderate impairment (Child-Pugh A or B), use with caution; consider starting at 1 mg once daily and titrate slowly.
Not recommended for use in pediatric patients for hypogonadism; for delayed puberty, IM testosterone cypionate 50 mg every 4 weeks initially, titrating upward as needed.
Safety and effectiveness in pediatric patients have not been established. Not recommended for use in children.
Start at lower end of dosing range (e.g., 50-100 mg every 2-4 weeks) due to increased risk of prostate enlargement and cardiovascular events; monitor serum testosterone levels and adjust accordingly.
Use cautiously due to increased risk of orthostatic hypotension, dizziness, and falls. Start at 1 mg once daily, titrate slowly. Monitor blood pressure carefully.
Prolonged use of high doses of testosterone has been associated with an increased risk of hepatocellular carcinoma.
None
Risk of polycythemia (monitor hematocrit), edema in patients with cardiac/renal/hepatic disease, accelerated growth in prepubertal males (monitor bone age), gynecomastia, sleep apnea exacerbation, prostate hyperplasia/carcinoma (monitor PSA), decreased spermatogenesis, elevated blood pressure, hyperlipidemia.
Orthostatic hypotension and syncope, especially with first dose ('first-dose effect'),Risk of intraoperative floppy iris syndrome (IFIS) during cataract surgery,Hepatic impairment may decrease metabolism,Priapism (rare),Drowsiness/somnolence, caution with operating machinery
Known or suspected prostate carcinoma, male breast carcinoma, pregnancy, hypersensitivity to testosterone cypionate, severe hepatic/renal/cardiac disease (relative), hypercalcemia (in patients with immobility).
Hypersensitivity to doxazosin or quinazolines,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension,Severe hepatic impairment
No significant food interactions. Limit alcohol consumption as it may increase risk of liver damage. Grapefruit juice may interfere with testosterone metabolism; avoid excessive intake.
Avoid grapefruit and grapefruit juice as they may increase drug levels. No other significant food interactions.
Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and third trimester exposure can also cause virilization. No adequate studies exist; use only if clearly needed for maternal condition, though use in pregnancy is generally avoided.
FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and well-controlled studies in pregnant women. Potential fetal risks include possible hypotension and reduced placental perfusion, especially in the second and third trimesters. Use only if potential benefit justifies risk.
Testosterone is excreted into breast milk in low concentrations; M/P ratio not reported. Theoretical risk of androgenic effects in male infants (e.g., masculinization). Use with caution only if maternal benefit outweighs potential risk. Consider alternative therapies while breastfeeding.
Doxazosin is excreted in human milk. The milk-to-plasma ratio is not reported. Caution is advised; monitor infant for signs of hypotension. Consider alternative therapy in hypertensive mothers during breastfeeding.
No specific dose adjustment studies exist. Pharmacokinetic changes during pregnancy (increased clearance, volume of distribution) may reduce efficacy, but use of testosterone cypionate during pregnancy is contraindicated. If essential, dose may need titration to maintain desired androgen levels; however, risk outweighs benefit.
No specific dose adjustments recommended for pregnancy. However, consider increased clearance and volume of distribution, especially in third trimester. Start with lowest effective dose (1 mg/day) and titrate based on blood pressure response. May require more frequent monitoring.
Testosterone cypionate is a long-acting injectable androgen. Monitor hematocrit and hemoglobin due to risk of polycythemia. Use with caution in patients with sleep apnea, benign prostatic hyperplasia, or cardiovascular disease. Check serum testosterone levels 1 week after injection to assess adequacy. For men with hypogonadism, avoid in those with untreated hyperprolactinemia or pituitary tumor.
First-dose syncope can occur; start with 1 mg at bedtime. Titrate slowly based on standing blood pressure. Monitor for orthostatic hypotension, especially in elderly. May cause intraoperative floppy iris syndrome (IFIS) during cataract surgery. Also used for benign prostatic hyperplasia (BPH) and hypertension.
Inject deeply into the muscle (gluteal or thigh) to reduce pain and risk of abscess.,Do not use if you have breast cancer, prostate cancer, or are pregnant.,Report swelling in ankles, difficulty breathing, or severe headache immediately.,Do not take with blood thinners like warfarin without consulting your doctor.,Expect possible mood changes, increased acne, or hair loss. Monitor for priapism.,Regular blood tests are required to check red blood cell count, liver function, and prostate health.
Take the first dose at bedtime to minimize dizziness.,Avoid sudden standing; rise slowly from sitting or lying positions.,May cause drowsiness; do not drive until you know how the medication affects you.,Avoid alcohol, as it can increase dizziness and drowsiness.,Inform your surgeon if you are taking this drug before cataract surgery.,Do not skip doses or discontinue abruptly; consult your doctor.
"Chlorpropamide, a sulfonylurea antidiabetic agent, stimulates pancreatic insulin secretion, while testosterone may enhance insulin sensitivity and reduce blood glucose levels. Concurrent use can lead to additive hypoglycemic effects, increasing the risk of hypoglycemia, particularly in patients with diabetes. This interaction is of clinical concern as it may necessitate dose adjustments of chlorpropamide to prevent hypoglycemic episodes."
"Flunisolide, a corticosteroid with mineralocorticoid activity, can potentiate the sodium- and water-retaining effects of testosterone, leading to an increased risk of edema, hypertension, and exacerbation of heart failure. This interaction is particularly significant in patients with pre-existing cardiovascular conditions, as the combined effects on fluid balance may require dose adjustments or closer monitoring."
"Fluorometholone, a corticosteroid with mineralocorticoid activity, may enhance sodium and water retention induced by testosterone, particularly in patients with pre-existing cardiac or renal conditions. This interaction can lead to increased fluid retention, exacerbation of hypertension, and potential precipitation of congestive heart failure. The risk is greater with high doses or prolonged use of either agent."
"Rifampicin is a potent inducer of cytochrome P450 (CYP) 3A4, the primary enzyme responsible for the metabolism of doxazosin. Concurrent use significantly increases doxazosin clearance, reducing its plasma concentration and thereby diminishing its antihypertensive effect. This interaction may lead to loss of blood pressure control, necessitating dose adjustment or alternative therapy."
"Clemastine, a first-generation antihistamine, is primarily metabolized by hepatic cytochrome P450 enzymes, including CYP2D6 and CYP3A4. Doxazosin, an alpha-1 adrenergic receptor antagonist used for hypertension and benign prostatic hyperplasia, can inhibit these CYP isoenzymes, potentially leading to reduced clemastine clearance and elevated plasma concentrations. This may increase the risk of clemastine-related adverse effects such as sedation, anticholinergic toxicity (e.g., dry mouth, urinary retention), and paradoxical CNS stimulation, especially in elderly or renally impaired patients."
"Doxazosin, an alpha-1 adrenergic receptor antagonist, blocks vasoconstriction mediated by catecholamines, thereby opposing the vasopressor effects of ritodrine, a beta-2 adrenergic agonist that also possesses alpha-adrenergic activity. This pharmacodynamic antagonism can reduce the efficacy of ritodrine in achieving uterine relaxation and may lead to inadequate tocolysis or increased risk of maternal hypotension. Clinically, the combination may result in diminished tocolytic response and potential cardiovascular instability."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TESTOSTERONE CYPIONATE vs DOXAZOSIN MESYLATE, answered by our medical review team.
TESTOSTERONE CYPIONATE is a Androgen that works by Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.. DOXAZOSIN MESYLATE is a Alpha-1 Blocker that works by Selective antagonist of alpha-1 adrenergic receptors on vascular smooth muscle, causing vasodilation and reduced peripheral vascular resistance, leading to decreased blood pressure. Also relaxes smooth muscle in the prostate and bladder neck, improving urinary flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TESTOSTERONE CYPIONATE and DOXAZOSIN MESYLATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TESTOSTERONE CYPIONATE is: Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.. The standard adult dose of DOXAZOSIN MESYLATE is: Hypertension: Initial 1 mg PO once daily (morning or bedtime); may increase to 2 mg, 4 mg, 8 mg, or 16 mg once daily as needed. BPH: Initial 1 mg PO once daily, titrate to 2 mg, 4 mg, or 8 mg once daily. Maximum 8 mg/day for BPH, 16 mg/day for hypertension.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TESTOSTERONE CYPIONATE and DOXAZOSIN MESYLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TESTOSTERONE CYPIONATE is classified as Category D/X. Testosterone cypionate is contraindicated in pregnancy. Androgenic effects may cause virilization of female fetus if exposed during organogenesis (first trimester). Second and thir. DOXAZOSIN MESYLATE is classified as Category A/B. FDA Pregnancy Category C. In animal studies, doxazosin showed no teratogenic effects in rats and rabbits at doses up to 20 and 8 mg/kg/day, respectively. There are no adequate and . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.